Juvisé Pharmaceuticals in the news
Global essential medicine provider
Tamtam found 20 recent articles about Juvisé Pharmaceuticals.
- Juvisé Pharmaceuticals : des médicaments essentiels, des responsabilités concrètes – L’interview d’Emilie Gounon
Juvisé Pharmaceuticals focuses on securing the supply chain for essential medicines while manufacturing 95% of its products within Europe.
- Juvisé Pharmaceuticals a entériné les nominations de Frédéric Mascha en tant qu’Executive Chairman et Président du comité de surveillance et de Renaud Sermondade en tant que nouveau CEO du groupe
Leadership changes at Juvisé Pharmaceuticals involve founder Frédéric Mascha moving to Executive Chairman and Renaud Sermondade taking over as CEO to drive M&A and global growth.
- White & Case advises Hayfin Capital Management on €550 million Juvisé Pharmaceuticals refinancing
Hayfin Capital Management provided €550 million in unitranche financing to Juvisé Pharmaceuticals for debt refinancing and acquisition capital.
- Juvisé Pharmaceuticals a entériné les nominations de Frédéric Mascha en tant qu’Executive Chairman et Président du comité de surveillance et de Renaud Sermondade en tant que nouveau CEO du groupe
Frédéric Mascha is transitioning to Executive Chairman and appointing Renaud Sermondade as the new CEO to lead growth and M&A strategies.
- Juvisé Pharmaceuticals Formally Approved the Appointments of Frédéric Mascha as Executive Chairman and Chairman of the Supervisory Committee and the Nomination of Renaud Sermondade as the Group’s New CEO
Juvisé Pharmaceuticals has restructured its top leadership with Frédéric Mascha becoming Executive Chairman and Renaud Sermondade joining as the new CEO to drive international M&A growth.
- Juvisé Pharmaceuticals Formally Approved the Appointments of Frédéric Mascha as Executive Chairman and Chairman of the Supervisory Committee and the Nomination of Renaud Sermondade as the Group’s New CEO
Juvisé Pharmaceuticals appointed Frédéric Mascha as Executive Chairman and Renaud Sermondade as the new CEO, effective July 1, 2026.
- Latham conseille Juvisé Pharmaceuticals sur un refinancement de 550 millions d'euros
Juvisé Pharmaceuticals secured 550 million euros in refinancing and M&A funding from Hayfin Capital Management.
- Latham conseille Juvisé Pharmaceuticals sur un refinancement de 550 millions d'euros
Juvisé Pharmaceuticals obtained 550 million euros in refinancing led by Hayfin Capital Management, with 150 million euros allocated for future M&A.
- Juvisé soigne son passif et voit loin
Juvisé Pharmaceuticals refinanced its debt and continues its strategy of acquiring established drugs like Ponvory to drive growth.
- France: Juvisé Pharmaceuticals secures €550m refinancing from Hayfin Capital Management
French specialty pharma Juvisé Pharmaceuticals secured €550 million in refinancing to fund future acquisitions and manage debt.
- Juvisé, le laboratoire qui rachète des médicaments délaissés, lève des fonds pour grossir
French laboratory Juvisé is raising capital to expand its business of acquiring and commercializing established medicines divested by Big Pharma.
- Agilité et excellence : les principes actifs de la réussite chez Juvisé Pharmaceuticals – L’interview de Fiona Lecrinier
Juvisé Pharmaceuticals is expanding its global footprint and team to manage a growing portfolio of essential medicines while planning significant recruitment through 2026.
- Juvisé acquires rights to MS therapy Ponvory outside North America
Juvisé Pharmaceuticals acquired the international rights for the multiple sclerosis drug Ponvory from a Johnson & Johnson subsidiary.
- Juvisé Pharmaceuticals acquiert les droits d'un médicament de J&J en dehors des États-Unis et du Canada
Juvisé Pharmaceuticals acquired the international rights for the multiple sclerosis drug Ponvory from Johnson & Johnson to drive strategic growth.
- Juvisé licenses J&J’s MS drug Ponvory for marketing outside North America
Juvisé Pharmaceuticals acquired international marketing and manufacturing rights for Johnson & Johnson's multiple sclerosis drug Ponvory to drive a 38% revenue increase.
- Juvisé, le laboratoire pharmaceutique qui ranime des médicaments délaissés
Juvisé Pharmaceuticals acquires and redistributes mature, essential medical molecules that major laboratories no longer consider strategic priorities.
- France: Juvisé Pharmaceuticals refinances funding raised to acquire rights to Pylera
Juvisé Pharmaceuticals finalized a €400m refinancing package to fund its global acquisition of the gastro-intestinal drug Pylera.
- French Juvisé buys gastro product in €400M finance deal
Juvisé Pharmaceuticals acquired the gastrointestinal drug Pylera from AbbVie through a 400 million euro financing deal with Société Générale.
- Antibiotiques : Juvisé Pharmaceuticals acquiert les droits du Pylera
Juvisé Pharmaceuticals acquired the rights to Pylera from AbbVie for the treatment of Helicobacter pylori infections, raising 400 million euros from Société Générale.
- Juvisé Pharmaceuticals : Un acteur atypique dans le monde de la pharmacie
Juvisé Pharmaceuticals acquires established medicines from large firms and relocates their production to Europe to serve niche therapeutic areas globally.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Juvisé Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies